• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Live Link
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • News
    • Careers
Get started
Sign in
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through December 2025 

Real-time monitoring of respiratory virus-associated hospitalizations: Trends through December 2025 

by Truveta Research | Jan 23, 2026 | Research

Respiratory virus–associated hospitalizations increased substantially (+125.3%) in December 2025 and accounted for nearly 7% of all hospitalizations by the last week of the month. This increase was driven primarily by a rise in influenza-associated hospitalizations...
Rising use of robotic-assisted surgery in hysterectomy, cholecystectomy, and inguinal hernia repair

Rising use of robotic-assisted surgery in hysterectomy, cholecystectomy, and inguinal hernia repair

by Truveta Research | Jan 21, 2026 | Research

From 2018 to 2025, robotic-assisted surgery increased across hysterectomy, cholecystectomy, and inguinal hernia repair, with robotic use in cholecystectomy increasing more than six-fold over the study period. Across all procedures, patients with higher comorbidity...
GLP-1 RA prescription trends: January 2019 – December 2025

GLP-1 RA prescription trends: January 2019 – December 2025

by Truveta Research | Jan 20, 2026 | Featured research, Research

As of December 2025, GLP-1 RA prescriptions account for more than 7% of all prescriptions. Tirzepatide continues to be the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and Zepbound, respectively) and showed the largest...
Type 1 diabetes: New opportunities for research with Truveta Live Link

Type 1 diabetes: New opportunities for research with Truveta Live Link

by Truveta staff | Jan 15, 2026 | Research

Type 1 diabetes (T1D) affects far fewer people than type 2, but the stakes for each person are higher. It’s a lifelong, minute-by-minute autoimmune condition. People with T1D depend on insulin to survive, and small improvements in glucose control can translate into...
The first 90 days after stroke: What real-world data show

The first 90 days after stroke: What real-world data show

by Truveta staff | Jan 7, 2026 | Research

For people who experience a first non-cardioembolic ischemic stroke (NCIS) or transient ischemic attack (TIA), the danger doesn’t end at hospital discharge. New research presented at the 2025 World Stroke Congress shows that the risk of recurrent events and...
Delayed or absent first dose of measles, mumps, and rubella vaccination

Delayed or absent first dose of measles, mumps, and rubella vaccination

by Truveta Research | Jan 2, 2026 | Featured research, Research

Authors: Nina B. Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen G. Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
« Older Entries

Share this


Recent posts

  • Why I’m joining Truveta
  • Real-time monitoring of respiratory virus-associated hospitalizations: Trends through December 2025 
  • Rising use of robotic-assisted surgery in hysterectomy, cholecystectomy, and inguinal hernia repair

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Research

Resources

Blog

News

Careers

Privacy notice

Contact us

© Truveta 2026

Our website uses cookies to ensure you have the best experience.